The phase II MARGOT trial (NCT04425018) evaluates how well participants with stage II-III HER2+ BC respond to pre-operative treatment using one of two combinations: paclitaxel plus pertuzumab plus margetuximab or paclitaxel plus pertuzumab plus trastuzumab [63]. This evidence concerns the gene ERBB2 and breast cancer.